Article
Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent.
Blood cells, molecules & diseases - 1 Mar 2018
Rigano Paolo, De Franceschi Lucia, Sainati Laura, Piga Antonio, Piel Frédéric B, Cappellini Maria Domenica, Fidone Carmelo, Masera Nicoletta, Palazzi Giovanni, Gianesin Barbara, Forni Gian Luca
Abstract excerpt
We conducted the first nation-wide cohort study of sickle cell disease (SCD) in Italy, a Southern European country exposed to intense recent flux migration from endemic areas for SCD. We evaluate the impact of hydroxyurea on a total of 652 pediatric and adult patients from 33 Reference Centers for SCD (mean age 24.5±15years, 51.4% males). Hydroxyurea median treatment duration was 7years (range: <1year to 29years)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.